Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) received a Canadian Intellectual Property Office Notice of Allowance for a patent covering key aspects of its AMHR2-targeted ovarian cancer vaccine technology, exclusively licensed from Cleveland Clinic.

The allowance expands protection beyond an existing U.S. patent and supports Anixa’s broader cancer vaccine platform, including a breast cancer vaccine whose Phase 1 trial met all primary endpoints.

Positive

• Canadian Notice of Allowance for ovarian cancer vaccine patent protection
• Patent covers AMHR2-targeted immunogenic compositions for ovarian cancer prevention or treatment
• Builds on U.S. Patent No. 12,357,593 for AMHR2 vaccine technology
• Expands international intellectual property position for cancer vaccine platform
• Breast cancer vaccine Phase 1 trial met all primary endpoints

Negative

• None.

Market Context

This announcement highlights expansion of Anixa’s ovarian cancer vaccine intellectual property into ...

Analysis

This announcement highlights expansion of Anixa’s ovarian cancer vaccine intellectual property into Canada, complementing a previously issued U.S. patent and reinforcing its AMHR2-targeted, “retired protein” cancer vaccine strategy. Recent history shows parallel progress in breast cancer vaccine trials and ovarian cancer CAR-T data. Investors may watch for subsequent clinical milestones, additional international patents, and any future use of the company’s shelf registration as it advances these vaccine programs.

Key Figures

U.S. patent number: 12,357,593

1 metrics

U.S. patent number 12,357,593 U.S. patent covering ovarian cancer vaccine technology announced July 2025

Historical Context

5 past events · Latest: May 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 11	CAR-T survival update	Positive	+1.0%	Positive survival and safety observations from lira-cel Phase 1 ovarian cancer trial.
May 11	Data correction note	Positive	+1.0%	Correction release reiterating encouraging survival and safety data for lira-cel.
May 01	Investor TV interview	Positive	+4.7%	Bloomberg TV interview highlighting vaccines, CAR-T data and business model.
Apr 29	Mexican patent issued	Positive	-4.3%	Mexican patent issuance extending breast cancer vaccine IP protection into 2040s.
Apr 22	Conference presentation	Positive	+2.6%	ISCT 2026 presentation on lira-cel Phase 1 ovarian cancer CAR-T program.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has generally seen modest positive price reactions, though IP-related headlines have produced both gains and declines.

Recent Company History

Over the last few months, Anixa has highlighted progress across multiple oncology programs. Updates in April–May 2026 showcased positive survival data from its lira-cel ovarian cancer CAR-T Phase 1 trial and media outreach on its capital-efficient model and breast cancer vaccine results. The company also expanded IP around its breast cancer vaccine with a Mexican patent. Today’s Canadian Notice of Allowance continues this pattern of building a broad international patent estate around its cancer vaccine technologies.

Key Terms

amhr2, nucleic acid, polypeptide, brca, +2 more

6 terms

amhr2 medical

"encoding the anti-Müllerian hormone receptor 2 (AMHR2) polypeptide to elicit an AMHR2-specific immune response"

AMHR2 is the gene and protein that acts as the receptor for anti‑Müllerian hormone, a biological signal that helps control reproductive tissue growth and development. For investors, AMHR2 matters because it can serve as a biomarker or drug target: medicines that bind or block this receptor may treat fertility disorders, hormonal cancers, or related conditions, affecting clinical trial outcomes, regulatory approvals, and potential commercial value.

nucleic acid medical

"an immunogenic composition comprising a nucleic acid encoding the anti-Müllerian hormone receptor 2 (AMHR2) polypeptide"

Large biological molecules—DNA and RNA—that store and carry the genetic instructions for living things, like an instruction manual that tells cells what to build and how to behave. Investors pay attention because many diagnostics, therapies and vaccines are based on reading or manipulating these molecules; successes or setbacks in those products, manufacturing, patents or regulatory approval can materially affect a company’s prospects and valuation.

polypeptide medical

"encoding the anti-Müllerian hormone receptor 2 (AMHR2) polypeptide to elicit an AMHR2-specific immune response"

A polypeptide is a chain of amino-acid 'building blocks' linked together, like beads on a string that fold into a specific shape to carry out biological tasks. Investors care because many modern drugs, vaccines and diagnostic tools are based on polypeptides or their derivatives; changes in a company’s polypeptide-based pipeline, manufacturing capability, patent protection or regulatory progress can directly affect its future revenue and risk profile.

brca medical

"particularly among high-risk populations such as those carrying BRCA mutations or with a family history"

BRCA refers to two human genes (commonly called BRCA1 and BRCA2) that help repair damaged DNA; certain inherited changes in these genes greatly increase a person’s lifetime risk of some cancers. Investors watch BRCA-related news because discoveries, tests, or treatments tied to these genes can open or shrink markets for diagnostics, drugs and preventive services — like a safety recall changing demand for an entire product category.

phase 1 medical

"Our breast cancer vaccine recently completed a Phase 1 clinical trial, funded by a grant"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

immunogenic medical

"includes methods of administering an immunogenic composition comprising a nucleic acid encoding"

Immunogenic describes a drug or biological product’s ability to trigger the body’s immune system to respond, such as producing antibodies or activating immune cells. For investors this matters because strong or unintended immune responses can determine a product’s effectiveness, safety, regulatory approval, manufacturing complexity and commercial success—think of it like a smoke detector: you want it sensitive enough to detect threats but not so sensitive that it causes frequent false alarms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer

SAN JOSE, Calif., June 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology.

The allowed patent, exclusively licensed from Cleveland Clinic, includes methods of administering an immunogenic composition comprising a nucleic acid encoding the anti-Müllerian hormone receptor 2 (AMHR2) polypeptide to elicit an AMHR2-specific immune response to prevent or treat ovarian cancer.

Anixa's ovarian cancer vaccine, being developed in a collaboration between Cleveland Clinic and the National Cancer Institute (NCI), represents a novel approach to preventing and treating ovarian cancer, particularly among high-risk populations such as those carrying BRCA mutations or with a family history of the disease.

The Canadian Notice of Allowance expands the international scope of Anixa's intellectual property portfolio around its ovarian cancer vaccine technology and complements the Company's existing patent protection in the United States. In July 2025, Anixa announced the issuance of U.S. Patent Number 12,357,593 covering key aspects of its ovarian cancer vaccine technology, including broad claims related to methods of eliciting an immune response targeting AMHR2.

"This Canadian Notice of Allowance further strengthens the international patent protection around our ovarian cancer vaccine program and supports the novelty of our AMHR2-targeted immunoprevention approach," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "Together with our U.S. patent protection for ovarian cancer vaccine technology and our separate intellectual property portfolio for breast cancer vaccine technology, this allowance supports our strategy of building a broad cancer vaccine platform based on retired-protein targets. Our breast cancer vaccine recently completed a Phase 1 clinical trial, funded by a grant from the U.S. Department of Defense and conducted in collaboration with Cleveland Clinic, in which all primary endpoints were met."

Anixa's ovarian cancer vaccine is based on immunizing against AMHR2, a protein expressed in normal ovaries prior to menopause and also aberrantly expressed in certain types of ovarian cancer. This "retired" protein strategy, developed at Cleveland Clinic and licensed exclusively to Anixa, is designed to train the immune system to recognize and target cells associated with ovarian cancer while seeking to avoid harm to normal tissue.

By expanding its patent protection in Canada, Anixa is continuing to build a broader international intellectual property position around its cancer vaccine technologies. The Company believes this intellectual property foundation is important as it evaluates future clinical, regulatory and strategic development opportunities for its vaccine programs.

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-strengthens-international-patent-protection-for-ovarian-cancer-vaccine-technology-with-canadian-notice-of-allowance-302786606.html

SOURCE Anixa Biosciences, Inc.

FAQ

What did Anixa Biosciences (NASDAQ: ANIX) announce on June 1, 2026 about its ovarian cancer vaccine?

Anixa announced a Canadian Notice of Allowance for a patent covering its ovarian cancer vaccine technology. According to Anixa, the allowed claims address methods using AMHR2-targeted nucleic acid compositions to elicit immune responses for preventing or treating ovarian cancer, expanding its international intellectual property protection.

How does the Canadian patent Notice of Allowance impact Anixa Biosciences’ AMHR2 ovarian cancer vaccine IP?

The Canadian Notice of Allowance broadens Anixa’s patent coverage for its AMHR2-based ovarian cancer vaccine beyond the U.S. According to Anixa, this complements U.S. Patent No. 12,357,593 and strengthens its overall intellectual property position for future clinical, regulatory and strategic development decisions.

What is Anixa Biosciences’ AMHR2-targeted ovarian cancer vaccine technology?

Anixa’s ovarian cancer vaccine uses nucleic acids encoding the AMHR2 polypeptide to trigger an AMHR2-specific immune response. According to Anixa, the approach aims to prevent or treat ovarian cancer, especially in high-risk groups, by targeting a protein aberrantly expressed in certain ovarian cancers while seeking to spare normal tissue.

How does the Canadian patent allowance relate to Anixa (ANIX) collaborations with Cleveland Clinic and NCI?

The allowed Canadian patent covers vaccine technology exclusively licensed from Cleveland Clinic, underpinning Anixa’s collaborative program. According to Anixa, the ovarian cancer vaccine is being developed with Cleveland Clinic and the National Cancer Institute, and the new protection helps support this ongoing development partnership and long-term strategy.

What progress has Anixa Biosciences reported on its breast cancer vaccine program?

Anixa reported that its breast cancer vaccine program completed a Phase 1 clinical trial with all primary endpoints met. According to Anixa, the trial was funded by a U.S. Department of Defense grant and conducted with Cleveland Clinic, supporting its broader retired-protein cancer vaccine platform strategy.

What is Anixa Biosciences’ retired-protein cancer vaccine strategy based on AMHR2 and other targets?

Anixa’s strategy focuses on vaccinating against “retired” proteins, such as AMHR2, expressed before menopause and in certain cancers. According to Anixa, this Cleveland Clinic–developed approach is intended to train the immune system to attack cancer-associated cells while aiming to limit damage to normal tissues.